

Substitute for form 1449A/PTO				Application Number		To Be Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date		Herewith
				First Named Inventor		Mattias Hällbrink et al.
				Art Unit		To Be Assigned
				Examiner Name		To Be Assigned
Sheet	1	of	2	Attorney Docket Number		20747/230

10/12 Rec'd PCT/PTO 0 6 DEC 2004

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	1	US-2002/031818 A1	03/14/2002	Ronai et al.	
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				
	2	WO	02/18572 A	03/07/2002	Aventis Pharmaceuticals Inc.		
	3	WO	02/02595 A	01/10/2002	Synt EM S.A.		
	4	WO	02/062823 A	08/15/2002	Yale University		
	5	WO	02/052583 A	07/04/2002	Bejed Inc.		
	6	WO	00/34308 A	06/15/2000	Washington University		
	7	WO	02/064453 A	08/22/2002	Brandname Properties PTY Ltd.		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	8	Sandberg et al., "New Chemical Descriptors Relevant for the Design of Biologically Active Peptides. A Multivariate Characterization of 87 Amino Acids," <i>Journal of Medicinal Chemistry</i> 41:2481-2491 (1998)	
	9	Lindgren et al., "Cell-Penetrating Peptides," <i>Trends in Pharmacological Sciences</i> 21(3):99-103 (2000)	
	10	Derossi et al., "Trojan Peptides: The Penetratin System for Intracellular Delivery," <i>Trends in Cell Biology</i> 8(2):84-87 (1998)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	To Be Assigned
				Filing Date	Herewith
				First Named Inventor	Mattias Hällbrink et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	2	of	2	Attorney Docket Number	20747/230

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	11	Vives et al., "A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates Through the Plasma Membrane and Accumulates in the Cell Nucleus," <i>Journal of Biological Chemistry</i> 272(25):16010-16017 (1997)	
	12	Mi et al., "Characterization of a Class of Cationic Peptides Able to Facilitate Efficient Protein Transduction In Vitro and In Vivo," <i>Molecular Therapy</i> 2(4):339-347 (2000)	
	13	Dokka et al., "Cellular Delivery of Oligonucleotides by Synthetic Import Peptide Carrier," <i>Pharmaceutical Research</i> 14(12):1759-1764 (1997)	
	14	Kircheis et al., "Design and Gene Delivery Activity of Modified Polyethylenimines," <i>Advanced Drug Delivery Reviews</i> 53(3):341-358 (2001)	
	15	Hashida et al., "Fusion of HIV-1 Tat Protein Transduction Domain to Poly-Lysine as a New DNA Delivery Tool," <i>British Journal of Cancer</i> 90(6):1252-1258 (2004)	
	16	Tréhin et al., "Chances and Pitfalls of Cell Penetrating Peptides for Cellular Drug Delivery," <i>European Journal of Pharmaceutics and Biopharmaceutics</i> 58(2):209-223 (2004)	
	17	Ignatovich et al., "Complexes of Plasmid DNA with Basic Domain 47-57 of the HIV-1 Tat Protein are Transferred to Mammalian Cells by Endocytosis-Mediated Pathways," <i>Journal of Biological Chemistry</i> 278(43):42625-42636 (2003)	
	18	Perales et al., "An Evaluation of Receptor-Mediated Gene Transfer Using Synthetic DNA-Ligand Complexes," <i>European Journal of Biochemistry</i> 226(2):255-266 (1994)	
	18	Wagner et al., "Transferrin-Polycation-DNA Complexes: The Effect of Polycations on the Structure of the Complex and DNA Delivery to Cells," <i>Proceedings of the National Academy of Sciences of USA</i> 88(10):4255-4259 (1991)	
	20	Singh et al., "Peptide-Based Intracellular Shuttle Able to Facilitate Gene Transfer in Mammalian Cells," <i>Bioconjugate Chemistry</i> 10(5):745-754 (1999)	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.